ROTTERDAM, Netherlands and SAN DIEGO, March 17, 2020 /PRNewswire/ -- SkylineDx shares research showing that multiple myeloma (blood cancer) patients...
Myeloma NZ
Myeloma and the Coronavirus
With rising community concern about the novel coronavirus or COVID-19, Myeloma Australia would like to provide the following information sheet...
Minimal Residual Disease Assessment Within the Bone Marrow of Multiple Myeloma: A Review of Caveats, Clinical Significance and Future Perspectives
There is an increasing clinical interest in the measure and achievement of minimal residual disease (MRD) negativity in the bone marrow of Multiple...
Multiple Myeloma Research Review
Highlights include: Daratumumab + standard care in newly diagnosed MM OS with daratumumab + bortezomib/melphalan/prednisone in newly diagnosed MM...
New CAR T-cell Therapy Shows Early Promise Against Multiple Myeloma in Lab Study
A new CAR T-cell therapy for people with multiple myeloma has been successfully created and tested in cell-based experiments and a mouse model, a...
Organ responses with daratumumab therapy in previously treated AL amyloidosis
Immunoglobulin light chain amyloidosis (AL amyloidosis) involves deposition of abnormally folded light chains into a wide range of tissues causing...
Sanofi Partners to Develop Diagnostic Test for Multiple Myeloma Patients on Potential Therapy
Sanofi announced that it partnered with Sebia to develop a new multiple myeloma diagnostic test that will help to mitigate the interference of...
ALCYONE Update: Adding Daratumumab to VMP Improves Survival in Transplant-Ineligible Myeloma
In patients with newly diagnosed multiple myeloma (MM) who are ineligible for high-dose chemotherapy and transplantation, adding daratumumab to...
Cancer drug funding welcomed
Mark Wellington cherished the final years he spent with his wife after she was diagnosed with multiple myeloma. Now he wants Pharmac to make good on...
Newsletter: January 2020
Happy New Year to everybody. It was a very busy and productive year in 2019. Thanks to everyone who has contributed in so many different ways. The...
Myeloma NZ calls on Pharmac to make good on access deal
Myeloma New Zealand is today calling on Pharmac to make good on their proposal to widen access to blood cancer treatment lenalidomide (Revlimid)...
Pharmac to widen treatment access for myeloma – New Zealand’s second most common blood cancer
Media Release In a move welcomed by patient advocacy group Myeloma New Zealand, drug buying agency Pharmac has proposed to widen access to blood...